Nilotinib for First-line Newly Diagnosed CML-CP Patients

Clinical trial NCT03942094 · UNKNOWN

Trial details

NCT number: NCT03942094
Sponsor: Shenzhen Second People's Hospital
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Myeloid Leukemia, Chronic Phase Nilotinib

Start date: 2019-06-01
Primary completion: 2023-06-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.